InVision logo

 

Bringing World-Leading ctDNA Expertise to the Clinic

Broad molecular profiling for targeted cancer care

Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge. The InVision® proprietary platform is a tagged-amplicon sequencing method, which allows amplification and deep sequencing of genomic regions spanning thousands of bases from individual copies of fragmented DNA.

InVision logo - Cancer Research

Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge.

Representation of Liquid Biopsy - Plasma Collection DNA extraction

Plasma collection DNA extraction

Representation of ctDNA analysis chart

ctDNA analysis

Bioinformatics analysis representation

Bioinformatics analysis

Oncology report generated

Oncology report generated

InVision - exceptional level of sensitivity and comprehensive coverage

Stand-out Sensitivity

InVision® has been developed to provide an exceptional level of sensitivity, while retaining a comprehensive coverage.

>99% of single nucleotide variants at an allele frequency of 0.25%-0.33% and >50% at an allele frequency of 0.06%-0.08%.

Our Technology

Our Solutions

Latest News